NCT04924192 - A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer | Biotech Hunter

Enrollment

126

Participants

Timeline

Start Date

August 18, 2021

Primary Completion Date

May 23, 2023

Study Completion Date

December 30, 2023

Conditions

Advanced Lung Carcinoma

Interventions

DRUG

TQB3616 capsules

A CDK4/6 kinase inhibitor

DRUG

Anlotinib Hydrochloride capsules

A multi-target receptor tyrosine kinase inhibitor

DRUG

Irinotecan Hydrochloride for Injection

An inhibitor of DNA topoisomerase Ⅰ

Trial Locations (7)

RECRUITING

Chongqing University Cancer Hospital, Chongqing

RECRUITING

Guizhou Provincial People's Hospital, Guiyang

RECRUITING

West China Hospital of Sichuan University, Chengdou

RECRUITING

Yunnan Cancer Hospital, Kunming

RECRUITING

The Second Affiliated Hospital of PLA Air Force Military Medical University, Xi’an

RECRUITING

The First Hospital of Lanzhou University, Lanzhou

RECRUITING

Sichuan Cancer Hospital, Chengdu